Detalhe da pesquisa
1.
A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
Br J Clin Pharmacol
; 86(6): 1139-1149, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32022282
2.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Cancer Immunol Immunother
; 68(5): 799-812, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770959
3.
Clonal evolution of CD8+ T cell responses against latent viruses: relationship among phenotype, localization, and function.
J Virol
; 89(1): 568-80, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25339770
4.
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
BMC Cancer
; 14: 748, 2014 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25288198
5.
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Vaccines (Basel)
; 12(4)2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38675770
6.
Analysis of stem-cell-like properties of human CD161++IL-18Rα+ memory CD8+ T cells.
Int Immunol
; 24(10): 625-36, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22836020
7.
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Vaccine X
; 14: 100307, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37131960
8.
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant.
Vaccines (Basel)
; 10(4)2022 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35455257
9.
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.
Vaccine X
; 11: 100189, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35791320
10.
Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
Kidney Int
; 78(9): 934-40, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20703211
11.
RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.
Vaccine
; 37(13): 1819-1826, 2019 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30797640
12.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
J Immunother Cancer
; 7(1): 38, 2019 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30736848
13.
Alloantigen-induced regulatory CD8+CD103+ T cells.
Hum Immunol
; 69(11): 737-44, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18822329
14.
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.
Oncoimmunology
; 5(12): e1249560, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28123889
15.
Immunosenescence and Cytomegalovirus: where do we stand after a decade?
Immun Ageing
; 7: 13, 2010 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20822513
16.
A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.
Hum Vaccin Immunother
; 9(10): 2263-76, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23921513
17.
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.
Cancer Res
; 69(21): 8412-9, 2009 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19843860